Keywords
COVID-19
SARS-CoV-2
Coronavirus
Adolescent
How to Cite
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
Abstract
Objective: To analyze the clinical characteristics and 12-month progress of pediatric patients with Cystic Fibrosis (CF) followed at a Brazilian CF center. Case details: Among the patients followed at a pediatric CF center from 2020 to 2022, five (7.1%) presented severe COVID-19. These patients had a mean age of 17 years old (SD ±0.9) at the time of SARS-CoV-2 infection, resulting in hospital length of stay ranging from 2 to 51 days (25.6 days on average, SD ±15.1), requiring respiratory support and ICU admission in three cases. The analysis revealed a temporary reduction in Body Mass Index (BMI), compromised severity scores, and lung function decay after the infection. Partial recovery of lung function and BMI was observed in two of the patients who started CFTR modulator therapy during the study period. Despite acute complications, the 12-month evolution was considered satisfactory, and there were no deaths. Final considerations: Despite the negative impact on the health of the studied CF patients during acute SARS-CoV-2 infection, there were no deaths or negative repercussions during the subsequent year after the infection.
References
BAIN R, et al. Clinical characteristics of SARS-CoV-2 infection in children with cystic fibrosis: An international observational study. Revista Eletrônica Journal of Cystic Fibrosis, 2021; 20(1): 25–30.
BIONDO C, et al. SARS-CoV-2 Infection in Patients with Cystic Fibrosis: What We Know So Far. Revista Eletrônica Life (Basel), 2022; 12(12): 2087.
BRASIL. Nota rápida de evidência: Observações sobre condições de risco para o agravamento ou morte por COVID-19. Disponível em: https ://www.arca.fiocruz.br/bitstream/handle/icict/42575/Nota%20t%E9cnica%20r%E1pida_Condicoes%20de%20risco%20e%20Covid%2019_NR01_2020.pdf;jsessionid=4A7C43331D5C124486F9CFFCC6F9F4F7?sequence=2. Acessado em: 24 de setembro de 2020.
BURGEL PR, GOSS C. COVID-19 outcomes in people with cystic fibrosis. Revista Eletrônica Current Opinion in Pulmonary Medicine, 2021; 27(6): 538–543.
CARR SB, et al. Factors associated with clinical progression to severe COVID-19 in people with cystic fibrosis: A global observational study. Revista Eletrônica Journal of Cystic Fibrosis, 2022; 21(4): e221-e231.
CAMARGO CC, et al. Características clínicas e desfechos de casos incidentes de COVID-19 em adultos não vacinados com fibrose cística no sul do Brasil: estudo prospectivo de coorte realizado durante o primeiro ano da pandemia de COVID-19. Revista Eletrônica Jornal Brasileiro de Pneumologia, 2022; 48(6): e20220265.
COLOMBO C, et al. SARS-CoV-2 infection in cystic fibrosis: A multicentre prospective study with a control group, Italy, February-July 2020. Revista Eletrônica PLOS ONE, 16(5): e0251527.
CORVOL H, et al. COVID‐19 and pediatric pulmonology: Feedback from an expert center after the first year of the pandemic. Revista Eletrônica Pediatric Pulmonology, 2023; 58: 392–397.
CORVOL H, et al. Cumulative Incidence and Risk Factors for Severe Coronavirus Disease 2019 in French People With Cystic Fibrosis. Revista Eletrônica Clinical Infectious Diseases, 2022; 75(12): 2135-2144.
GBEFC. Registro Brasileiro de Fibrose Cística ano 2020. Disponível em: http ://portalgbefc.org.br/ckfinder/userfiles/files/REBRAFC_2020.pdf. Acessado em 24 de setembro de 2023.
GRASEMANN H, RATJEN F. Cystic Fibrosis. Revista Eletrônica The New England Journal of Medicina, 2023; 389(18): 1693-1707.
JUNG A, et al. Factors for severe outcomes following SARS-CoV-2 infection in people with cystic fibrosis in Europe. Revista Eletrônica ERJ Open Res, 2021; 7: 00411-2021.
LIDINGTON D, BOLZ SS. A Scientific Rationale for Using Cystic Fibrosis Transmembrane Conductance Regulator Therapeutics in COVID-19 Patients. Revista Eletrônica Frontiers in Physiology, 2020; 11: 583862.
MANTI S, et al. SARS-CoV-2 infection in pediatric population. Revista Eletrônica Acta Biomed, 2020; 91(11): e2020003.
MCCLENAGHAN E, et al. The global impact of SARS-CoV-2 in 181 people with cystic fibrosis. Revista Eletrônica Journal of Cystic Fibrosis, 2020; 19(6): 868-871.
MEDINO P, et al. Impact of COVID-19 on Lung Disease in People with Cystic Fibrosis: A 6-Month Follow-Up Study on Respiratory Outcomes. Revista Eletrônica Biomedicines, 2022; 10(11): 2771.
MILES B, et al. The Impact of Elexacaftor/Ivacaftor/Tezacaftor on Cystic Fibrosis Patients Who Acquire COVID-19 Infection. Revista Eletrônica Cureus, 2022; 14(9): e29276.
MONDEJAR-LOPEZ P, et al. Impact of SARS-CoV-2 infection in patients with cystic fibrosis in Spain: Incidence and results of the national CF-COVID19-Spain survey. Revista Eletrônica Respiratory Medicine, 2020; 106062.
SANTANA NN, et al. Fatores associados à qualidade de vida em crianças e adolescentes com Fibrose Cística. Revista Eletrônica Revista Paulista de Pediatria, 2020. 38: e2018397.
SCHNAPP Z, et al. Decreased fecal calprotectin levels in cystic fibrosis patients after antibiotic treatment for respiratory exacerbation. Revista Eletrônica Journal of Pediatric Gastroenterology and Nutrition, 2019; 68(2): 282-284.
SOCIEDADE BRASILEIRA DE PEDIATRIA (SBP). COVID-19 em crianças: envolvimento respiratório. 2020. Disponível em: https ://www.sbp.com.br/fileadmin/user_upload/22430d-NA_-_COVID-19_em_criancas-_envolvimento_respiratorio.pdf. Acessado em 24 de setembro de 2023.
TERLIZZI V, et al. Risk factors for severe COVID-19 in people with cystic fibrosis: A systematic review. Revista Eletrônica Frontiers in Pediatrics, 2022; 10: 958658.